title: Early relapse is associated with high serum soluble interleukin-2 receptor after the sixth cycle of R-CHOP chemotherapy in patients with advanced diffuse large B-cell lymphoma.
abstract: The clinical significance of serum soluble interleukin-2 receptor (sIL2R) levels was retrospectively assessed in patients with advanced diffuse large B-cell lymphoma (DLBCL). Twenty-one patients, who were newly-diagnosed with advanced DLBCL (stage III and IV) between 2006 and 2009, were evaluated. The median follow-up period was 37 months. All patients received 6-8 cycles of chemotherapy with rituximab in combination with doxorubicin, cyclophosphamide, vincristine, and prednisolone (CHOP)-like regimens and attained complete remission. Although all patients reached complete remission, six patients experienced disease relapse within 1 year after treatment completion. The overall survival was significantly poorer in patients with relapse than in patients with durable remission. The sIL2R levels after the sixth cycle of treatment were significantly higher in the relapse group than in the non-relapse group. Thus, the present study suggests sIL2R levels to be a valuable predictor for the prognosis of patients with advanced DLBCL.
authors.affiliation: Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, 23 Shimoaizuki, Matsuoka, Eiheiji Fukui, 910-1193, Japan. tyamauch@u-fukui.ac.jp
authors.forename: Takahiro
authors.initials: T
authors.lastname: Yamauchi
authors.forename: Yasufumi
authors.initials: Y
authors.lastname: Matsuda
authors.forename: Mihoko
authors.initials: M
authors.lastname: Takai
authors.forename: Toshiki
authors.initials: T
authors.lastname: Tasaki
authors.forename: Katsunori
authors.initials: K
authors.lastname: Tai
authors.forename: Naoko
authors.initials: N
authors.lastname: Hosono
authors.forename: Eiju
authors.initials: E
authors.lastname: Negoro
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ikegaya
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Takagi
authors.forename: Shinji
authors.initials: S
authors.lastname: Kishi
authors.forename: Akira
authors.initials: A
authors.lastname: Yoshida
authors.forename: Yoshimasa
authors.initials: Y
authors.lastname: Urasaki
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Iwasaki
authors.forename: Takanori
authors.initials: T
authors.lastname: Ueda
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols; D014408:Biomarkers, Tumor / Q000032:analysis / Q000097:blood*; D003520:Cyclophosphamide; D004317:Doxorubicin; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000097:blood* / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood* / Q000188:drug therapy / Q000473:pathology; D009367:Neoplasm Staging; D011241:Prednisone; D011379:Prognosis; D015375:Receptors, Interleukin-2 / Q000032:analysis / Q000097:blood*; D012189:Retrospective Studies; D000069283:Rituximab; D014750:Vincristine
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D014408:Biomarkers, Tumor; C571759:R-CHOP protocol; D015375:Receptors, Interleukin-2; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone